ONCOLYTIC IMMUNOTHERAPY Trademark

Trademark Overview

On Friday, March 15, 2024, a trademark application was filed for ONCOLYTIC IMMUNOTHERAPY with the United States Patent and Trademark Office. The USPTO has given the ONCOLYTIC IMMUNOTHERAPY trademark a serial number of 98452032. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Monday, October 7, 2024. This trademark is owned by CG Oncology, Inc.. The ONCOLYTIC IMMUNOTHERAPY trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical products for the treatment of cancer; pharmaceutical preparations and biological preparations for the treatment of cancer and immunological disorders; Biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumor necrosis factors; Chemical preparations for medical or pharmaceutical purposes, namely, for cancer treatment, oncology and immunotherapy for auto immune diseases; Pharmaceutical products, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing

Pharmaceutical research and development; Providing medical and scientific research information in the fields of oncology, autoimmune disorders, immunotherapy, immunotherapeutics, biotechnology, biopharmaceuticals, pharmaceuticals, therapies, diseases, and disorders
oncolytic immunotherapy

General Information

Serial Number98452032
Word MarkONCOLYTIC IMMUNOTHERAPY
Filing DateFriday, March 15, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateMonday, October 7, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical products for the treatment of cancer; pharmaceutical preparations and biological preparations for the treatment of cancer and immunological disorders; Biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumor necrosis factors; Chemical preparations for medical or pharmaceutical purposes, namely, for cancer treatment, oncology and immunotherapy for auto immune diseases; Pharmaceutical products, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing
Goods and ServicesPharmaceutical research and development; Providing medical and scientific research information in the fields of oncology, autoimmune disorders, immunotherapy, immunotherapeutics, biotechnology, biopharmaceuticals, pharmaceuticals, therapies, diseases, and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 15, 2024
Primary Code005
First Use Anywhere DateSaturday, July 1, 2023
First Use In Commerce DateSaturday, July 1, 2023
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, March 15, 2024
Primary Code042
First Use Anywhere DateSaturday, July 1, 2023
First Use In Commerce DateSaturday, July 1, 2023

Trademark Owner History

Party NameCG Oncology, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92618

Trademark Events

Event DateEvent Description
Sunday, March 17, 2024NEW APPLICATION ENTERED
Friday, August 9, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, September 12, 2024TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Wednesday, September 25, 2024ASSIGNED TO EXAMINER
Monday, October 7, 2024NON-FINAL ACTION WRITTEN
Monday, October 7, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, October 7, 2024NON-FINAL ACTION E-MAILED
Thursday, September 12, 2024TEAS VOLUNTARY AMENDMENT RECEIVED

Related Keywords

immunotherapy oncolytic pharmaceutical cancer treatment disorders blood preparations namely factors medical diseases